Press releases
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
More ▼
Key statistics
On Wednesday, Halozyme Therapeutics Inc (0J2O:LSE) closed at 39.41, -11.84% below its 52-week high of 44.71, set on Aug 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 39.41 |
Average volume | 76.80 |
---|---|
Shares outstanding | 127.05m |
Free float | 125.68m |
P/E (TTM) | 18.07 |
Market cap | 4.84bn USD |
EPS (TTM) | 2.11 USD |
Data delayed at least 20 minutes, as of May 01 2024 16:22 BST.
More ▼